High serum levels of CCL11/Eotaxin-1 are associated with diabetic sensorimotor polyneuropathy and peripheral nerve function but not with cardiac autonomic neuropathy in people with type 2 diabetes.

Autor: Aso Y; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Iijima T; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Jojima T; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Saito M; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Tanuma D; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Kase M; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Sakurai S; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Tomaru T; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan., Usui I; Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan.
Jazyk: angličtina
Zdroj: Postgraduate medicine [Postgrad Med] 2024 Apr; Vol. 136 (3), pp. 318-324. Date of Electronic Publication: 2024 Apr 29.
DOI: 10.1080/00325481.2024.2347196
Abstrakt: Aims: To investigate whether higher serum CCL11/Eotaxin-1, a biomarker for aging and neurodegenerative and neuroinflammatory disorders, is associated with diabetic sensorimotor polyneuropathy (DSPN), peripheral nerve dysfunction, and cardiac autonomic neuropathy in people with type 2 diabetes.
Methods: This cross-sectional study included 106 patients with type 2 diabetes and 40 healthy controls, matched for the age and sex distribution of the diabetes group as a whole. The CC chemokines CCL11/Eotaxin-1 and CCL22/MDC were measured in fasting serum samples. DSPN and peripheral nerve function were assessed by neurological examination and nerve conduction studies, and cardiac autonomic function, by heart rate variability (HRV) and corrected QT (QTc) time. The cardio-ankle vascular index (CAVI) was measured as a marker for arterial stiffness.
Results: Serum CCL11/Eotaxin-1 levels were significantly higher in diabetic patients than in healthy controls (183 ± 63.5 vs. 113.1 ± 38.5 pg/ml, p  < 0.001), but serum CCL22/MDC levels were not significantly different between the two groups. In the diabetes group, the serum CCL11/Eotaxin-1 level was positively correlated with ulnar and sural nerve conduction velocities ( p  = 0.0009, p  = 0.0208, respectively) and sensory nerve action potential ( p  = 0.0083), and CAVI ( p  = 0.0005), but not with HRV indices or QTc time, and serum CCL22/MDC was not significantly correlated with any indices of nerve conduction. In a model adjusted for age and duration of diabetes, serum CCL11/Eotaxin-1 was still associated with ulnar nerve conduction velocity ( p  = 0.02124). Serum CCL11/Eotaxin-1, but not CCL22/MDC, was significantly higher in patients with than in those without DSPN (208.2 ± 71.6 vs. 159.1 ± 45.1 pg/ml, respectively; p  < 0.0001).
Conclusions: Serum CCL11/Eotaxin-1 is elevated in patients with DSPN and is associated with peripheral nerve dysfunction, in particular sensory nerve conduction velocity, suggesting that serum CCL11/Eotaxin-1 may be a potential biomarker for DSPN.
Clinical Trial Registration: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000040631).
Databáze: MEDLINE
Externí odkaz: